Novartis’ mAb becomes first for migraines in EU
The European Commission has given its approval for Novartis’ Aimovig, the treatment designed specifically for patients with migraines.
Archives for August 1, 2018
China’s Bio-Thera begins trials to develop biosimilar to Actemra
A Phase I clinical trial to examine the safety and pharmacokinetics of BAT1806, an Actemra biosimilar, is to be conducted by Chinese pharmaceutical company Bio-Thera.
Pfizer: EU green light for Herceptin biosimilar, looks to US
The European Commission has approved Pfizer’s Trazimera, a biosimilar version of Roche’s best-selling oncology monoclonal antibody, Herceptin.